Almost three-quarters of women with inflammatory bowel disease (IBD) who underwent assisted reproductive technology (ART) achieved pregnancy, according to new prospective study data. The findings suggest embryo transfer is significantly more effective than intrauterine insemination (IUI) for these patients, particularly those with prior pelvic surgery.
Study Results on Fertility Treatment Success
The WIsDoM (Women with Inflammatory Bowel Disease and Motherhood) study tracked 421 women with IBD attempting pregnancy across 30 U.S. and Canadian centers. Of the 67 women who underwent fertility treatment, 73% became pregnant – 41% of all 97 treatment attempts resulted in pregnancy overall.
Dr. Eugenia Shmidt of the University of Minnesota reported that embryo transfer achieved a 73% success rate compared to just 10% for IUI alone (odds ratio 24.0, 95% CI 8.0-70.0).
Among 39 women who underwent embryo transfer, 32 proceeded directly to the procedure without prior IUI cycles. The remaining seven completed an average of three IUI attempts before advancing to embryo transfer. After adjusting for confounders, the odds of pregnancy with embryo transfer versus IUI nearly doubled (adjusted odds ratio 44.0, 95% CI 8.9-221.0). No other variables – including disease activity, prior ART use, or surgery history – significantly affected outcomes when controlling for treatment modality.
Women undergoing fertility treatment were older (median 34 vs. 32 years) and had longer attempts to conceive (median 11 vs. 2 months). They also showed higher rates of prior fertility treatment (31.3% vs. 8.8%) and pelvic IBD surgery (16.4% vs. 5.4%), with more active disease at enrollment (56.7% vs. 43.5%). Repeat attempts were common, with 42% requiring multiple cycles averaging 2.45 IUI procedures and 1.23 embryo transfers.
Clinical Implications for IBD Patients
Clinicians should consider early referral to IVF with embryo transfer rather than prolonged IUI trials, especially for patients with previous pelvic surgery. While IUI success rates matched the general population, embryo transfer rates in this IBD cohort significantly exceeded the 45-50% typically seen in non-IBD populations. This difference indicates IBD patients may particularly benefit from embryo transfer strategies.
The observational study highlights knowledge gaps around real-world ART utilization in IBD patients and factors predicting pregnancy success. Monthly surveys captured conception attempts and outcomes over the planned 15-month enrollment period. Egg retrieval alone was performed by 15 women but counted separately from pregnancy attempts, which focused specifically on IUI and embryo transfer procedures.
After adjustment for potential confounders including disease duration, the analysis found that embryo transfer effectively overcomes disease- and surgery-related fertility barriers. The study’s authors emphasize that while ART effectiveness appears comparable between IBD and non-IBD populations, targeted treatment selection based on individual patient factors may optimize outcomes.
These findings align with existing understanding that some IBD patients experience reduced fertility, particularly during active disease or after pelvic surgery requiring rectal dissection. The prospective nature of the WIsDoM study provides valuable insights into how fertility treatments are actually utilized in clinical practice, addressing previous knowledge gaps about real-world application in this patient population. The data demonstrate that embryo transfer provides a viable path to parenthood for IBD patients facing fertility challenges.
